Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocugen (NASDAQ: OCGN ) stock is on the rise Tuesday after the clinical-stage biopharmaceutical company announced a new vaccine trial. According to a press release from the company, its vaccine for the flu and Covid-19 has been selected for clinical trial.

Why Is Ocugen (OCGN) Stock Up 5% Today?

MALVERN, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, will conduct a trial comparing the administration of Ocugen's mucosal vaccine candidate, OCU500, via two different mucosal routes, inhalation into the lungs and as a nasal spray.

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen's Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4 th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass.

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7 th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC.

Ocugen to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company's Business Advisory Board (BAB). The BAB was established in June 2023 to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's therapies around the world.

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC.

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

MALVERN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber congenital amaurosis (LCA) with mutation(s) in the CEP290 gene. This clinical study update is an extension of results provided by Ocugen on April 14, 2023, and includes additional subjects from the high dose group. The Company believes that OCU400—Ocugen's therapeutic approach, utilizing a proprietary modifier gene therapy platform—has the potential to be a gene-agnostic therapeutic for RP and LCA patients with inherited retinal degeneration.

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

Ocugen Inc. (NASDAQ:OCGN ) Q2 2023 Earnings Conference Call August 22, 2023 8:30 AM ET Company Participants Shankar Musunuri - Chief Executive Officer Arun Upadhyay - Chief Scientific Officer Tiffany Hamilton - Head of Corporate Communications Conference Call Participants Jennifer Kim - Cantor Fitzgerald Swayampakula Ramakanth - HC Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Capital Markets Operator Good morning and welcome to Ocugen's second quarter 2023 financial results and business update. Please note that this call is being recorded at this time.

Ocugen (OCGN) Q2 2023 Earnings Call Transcript

Conference Call and Webcast Tomorrow at 8:30 a.m. ET •  Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease •  OCU400 Clinical Study Results Update Expected This Quarter MALVERN, Pa.

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Tuesday, August 22, 2023.

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

Gevo

Ribbon Communications

Here's a personal story – while millionaire-maker stocks to buy seems like a fantastical notion, it's not an impossible one. Roughly two-and-a-half years ago, I shared how I bought my house free and clear thanks to cryptos.

3 Millionaire-Maker Growth Stocks to Buy Before the Window

Amyris

MannKind

Moderna

Novavax

Cassava Sciences Inc

VBI Vaccines

Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category.

7 Biotech Stocks to Sell in July

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company's Chairman, CEO and Co-Founder, Shankar Musunuri, PhD, MBA, and Chief Scientific Officer, Head of Research, Development and Medical, Arun Upadhyay, PhD, will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company's 2023 Annual Meeting of Shareholders (Annual Meeting) was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

Shares of Ocugen (NASDAQ: OCGN ) stock have been on the move today. Following a surge of more than 3% this morning, shares of OCGN stock have since settled down to an almost flat gain of 0.2%.

Can Pat Toomey Save Ocugen (OCGN) Stock?

MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company's differentiated capabilities; and promoting access to the Company's therapies around the world.

Ocugen, Inc. Announces Business Advisory Board

Novavax and Ocugen fell behind in the coronavirus vaccine race and their shares have plummeted. Now, both companies have revised their strategies.

Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?

Ocugen (NASDAQ: OCGN ) stock has trended steadily downward for the past six months, shedding almost 70% of its value. While things have looked bleak for some time, they took a turn for the worse yesterday.

5 Investors Betting Big on Ocugen (OCGN) Stock Right Now

Ocugen (NASDAQ: OCGN) stock price plunged hard on Wednesday after the company unveiled more plans to dilute shareholders. The penny stock retreated to a low of $0.440, the lowest point since 2020.

Ocugen stock price plummeted: dead cat bounce can't be ruled out

Ocugen (NASDAQ: OCGN ) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering. Ocugen has announced that it selling 30 million hares of OCGN stock for a total value of $16.5 million.

Why Is Ocugen (OCGN) Stock Down 22% Today?

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about May 26, 2023, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to 4,500,000 additional shares of its common stock.

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO International Convention taking place in Boston, Mass. from June 5-8, 2023.

Ocugen to Present at BIO International Convention 2023

Start Time: 08:30 January 1, 0000 9:05 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2023 Earnings Conference Call May 05, 2023, 08:30 AM ET Company Participants Shankar Musunuri - Chairman, CEO and Co-Founder Quan Vu - CFO and Chief Business Officer Sharon Choe - Head of IR Conference Call Participants Jennifer Kim - Cantor Fitzgerald Jonathan Aschoff - ROTH Capital Partners Uy Ear - Mizuho Securities Robert LeBoyer - Noble Capital Markets Swayampakula Ramakanth - H.C. Wainwright Daniil Gataulin - Chardan Operator Good morning, and welcome to the Ocugen's First Quarter 2023 Financial Results and Business Update Call.

News for Ocugen, Inc. Stock (OCGN)